BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Paige Introduces Alba: The AI-Powered Clinical Co-Pilot Transforming Diagnostics and Treatment in Pathology and Oncology

NextEdge Admin

06 Sep 2024

2 min 37 sec

Paige, a leader in next-gen AI technology, has unveiled Paige Alba™, a clinical-grade multimodal co-pilot designed to revolutionize personalized medicine and precision oncology. Powered by Paige’s Foundation Models, Alba delivers AI-driven patient insights in real-time, marking a significant step toward Artificial General Intelligence (AGI).

Alba integrates advanced computational pathology large vision models (LVMs) with conversational large language models (LLMs), providing a seamless, real-time experience for pathologists, oncologists, and clinical teams. This cohesive solution enhances diagnostics and clinical trials management, bringing together multiple AI-driven insights in one platform.

A standout feature of Alba is its ability to aggregate and summarize patient data from multiple sources, including Electronic Health Records (EHRs), Laboratory Information Systems (LIS), and Image Management Systems (IMS). By consolidating data, Alba reduces administrative burdens and allows pathologists to access comprehensive patient-specific summaries—including prior reports and radiology findings—within seconds, accelerating decision-making.

"Pathologists often lack the clinical context necessary for accurate diagnoses," said Dr. Juan Retamero, Medical VP at Paige. "Alba provides this context through its natural language processing and integration with other clinical systems, enhancing collaboration and resolving discrepancies between radiology and pathology."

Alba also leverages Paige’s AI portfolio, including Paige Omniscreen™, to analyze digital images, highlight areas suspicious for cancer, and support expert review. It consolidates clinical, pathological, and biomarker data, generating pathology reports that can be reviewed and approved using voice commands, improving diagnostic efficiency.

"Alba acts as a co-pilot, ensuring clinicians have timely, relevant information for complex decision-making," said Paige CEO Razik Yousfi.

Paige Alba™ is for research use only (RUO), not for use in diagnostic procedures.